Related Experiment Video
Updated: Dec 19, 2025

11:32
Fabrication of Biologically Derived Injectable Materials for Myocardial Tissue Engineering
Published on: December 20, 2010
15.4K
Why we should be avoiding periorificial mimetic muscles when injecting tissue fillers
Greg J Goodman1,2,3, Firas Al-Niaimi4,5,6, Cara McDonald7
1Monash University, Carlton, Vic., Australia.
Journal of Cosmetic Dermatology
|June 6, 2020
Summary
Injecting facial fillers into facial muscles, particularly around the eyes and mouth, increases risks of severe complications like clumping, swelling, and intravascular injection. Avoiding these muscular layers enhances patient safety.
Area of Science:
- Dermatology
- Plastic Surgery
- Aesthetic Medicine
Background:
- Facial fillers are widely used with generally good safety profiles.
- However, severe complications such as intravascular injection and late nodularity can occur.
- Injection depth is a critical factor in mitigating these risks.
Purpose of the Study:
- To investigate the implications of injecting facial fillers into the facial muscular layer.
- To identify potential adverse reactions associated with muscular layer injections.
Main Methods:
- A comprehensive literature review was conducted.
- Searched available databases for studies on facial filler injections into or around facial muscles.
- Focused on identifying links between injection site and adverse events.
Main Results:
- Literature indicates a higher incidence of adverse reactions when fillers are injected into the mimetic musculature.
- The periorbital and perioral regions' musculature are particularly implicated.
- These injections are associated with product clumping, displacement, and late-onset swelling or nodularity.
Conclusions:
- Injecting fillers into the perioral and perioral mimetic muscular layers increases risks of complications.
- These risks include product clumping, displacement, late nodularity, and swelling.
- Muscular layer injections, especially into sphincteric muscles, should be avoided to minimize adverse outcomes and intravascular injection risks.

